Literature DB >> 21739484

Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines.

Ashwani Khurana1, Han W Tun, Laura Marlow, John A Copland, Keith Dredge, Viji Shridhar.   

Abstract

Inactivation of von Hippel-Lindau (VHL), a tumor suppressor gene is often associated with clear cell renal cell carcinoma (ccRCC). VHL inactivation leads to multitude of responses including enhanced growth factor signaling such as bFGF2, SDF-1α, and HGF. Here, we have identified a novel VHL-inducible gene, heparan sulfatase 2 (HSulf-2) that attenuates heparan-binding growth factor such as bFGF2 signaling. VHL-mediated HIF-1 alpha degradation was essential to restore HSulf-2 expression. Mechanistically, HSulf-2 negatively regulated vimentin expression and knockdown of vimentin abolished cell migration. This study reveals a novel layer of regulation of heparan-binding growth factor signaling via modulation of heparan sulfate by HSulf-2 in ccRCC.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21739484      PMCID: PMC3192919          DOI: 10.1002/mc.20824

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  40 in total

1.  Cobalt induces hypoxia-inducible factor-1alpha (HIF-1alpha) in HeLa cells by an iron-independent, but ROS-, PI-3K- and MAPK-dependent mechanism.

Authors:  Anastasia Triantafyllou; Panagiotis Liakos; Andreas Tsakalof; Elena Georgatsou; George Simos; Sophia Bonanou
Journal:  Free Radic Res       Date:  2006-08

2.  HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.

Authors:  Keishi Narita; Julie Staub; Jeremy Chien; Kristy Meyer; Maret Bauer; Andreas Friedl; Sundaram Ramakrishnan; Viji Shridhar
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

3.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

4.  Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.

Authors:  C C Wykoff; C W Pugh; P H Maxwell; A L Harris; P J Ratcliffe
Journal:  Oncogene       Date:  2000-12-14       Impact factor: 9.867

5.  Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts.

Authors:  Sarah M Peterson; Andrea Iskenderian; Lynette Cook; Alla Romashko; Kristen Tobin; Michael Jones; Angela Norton; Alicia Gómez-Yafal; Michael W Heartlein; Michael F Concino; Lucy Liaw; Paolo G V Martini
Journal:  BMC Cancer       Date:  2010-08-13       Impact factor: 4.430

6.  The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.

Authors:  K Dredge; E Hammond; K Davis; C P Li; L Liu; K Johnstone; P Handley; N Wimmer; T J Gonda; A Gautam; V Ferro; I Bytheway
Journal:  Invest New Drugs       Date:  2009-04-09       Impact factor: 3.850

7.  Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis.

Authors:  Lina Liu; Junqi Qian; Harpreet Singh; Isabelle Meiers; Xiaoge Zhou; David G Bostwick
Journal:  Arch Pathol Lab Med       Date:  2007-08       Impact factor: 5.534

8.  Regulation of endocytosis via the oxygen-sensing pathway.

Authors:  Yi Wang; Olga Roche; Mathew S Yan; Greg Finak; Andrew J Evans; Julie L Metcalf; Bridgid E Hast; Sara C Hanna; Bill Wondergem; Kyle A Furge; Meredith S Irwin; William Y Kim; Bin T Teh; Sergio Grinstein; Morag Park; Philip A Marsden; Michael Ohh
Journal:  Nat Med       Date:  2009-03-01       Impact factor: 53.440

9.  HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1.

Authors:  Kenji Uchimura; Megumi Morimoto-Tomita; Annette Bistrup; Jessica Li; Malcolm Lyon; John Gallagher; Zena Werb; Steven D Rosen
Journal:  BMC Biochem       Date:  2006-01-17       Impact factor: 4.059

10.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.

Authors:  Ariel A Williams; John P T Higgins; Hongjuan Zhao; Börje Ljunberg; James D Brooks
Journal:  BMC Clin Pathol       Date:  2009-11-18
View more
  7 in total

1.  Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts.

Authors:  Ashwani Khurana; Deok Jung-Beom; Xiaoping He; Sung-Hoon Kim; Robert C Busby; Laura Lorenzon; Massimo Villa; Alfonso Baldi; Julian Molina; Matthew P Goetz; Viji Shridhar
Journal:  Clin Exp Metastasis       Date:  2013-02-15       Impact factor: 5.150

2.  Role of heparan sulfatases in ovarian and breast cancer.

Authors:  Ashwani Khurana; Daniah Beleford; Xiaoping He; Jeremy Chien; Viji Shridhar
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

3.  Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.

Authors:  Ashwani Khurana; Hiedi McKean; Hyunseok Kim; Sung-Hoon Kim; Jacie mcguire; Lewis R Roberts; Matthew P Goetz; Viji Shridhar
Journal:  Breast Cancer Res       Date:  2012-03-12       Impact factor: 6.466

4.  Impact of Sulfatase-2 on cancer progression and prognosis in patients with renal cell carcinoma.

Authors:  Shin Kumagai; Kei Ishibashi; Masao Kataoka; Toshiki Oguro; Yuichirou Kiko; Tomohiko Yanagida; Ken Aikawa; Yoshiyuki Kojima
Journal:  Cancer Sci       Date:  2016-11       Impact factor: 6.716

5.  A simple and robust vector-based shRNA expression system used for RNA interference.

Authors:  Xue-jun Wang; Ying Li; Hai Huang; Xiu-juan Zhang; Pei-wen Xie; Wei Hu; Dan-dan Li; Sheng-qi Wang
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

Review 6.  The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.

Authors:  Edward Hammond; Ashwani Khurana; Viji Shridhar; Keith Dredge
Journal:  Front Oncol       Date:  2014-07-24       Impact factor: 6.244

7.  Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer.

Authors:  DeokBeom Jung; Ashwani Khurana; Debarshi Roy; Eleftheria Kalogera; Jamie Bakkum-Gamez; Jeremy Chien; Viji Shridhar
Journal:  Sci Rep       Date:  2018-02-06       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.